A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of ASP1941 in Healthy Male Taiwanese Subjects

Inclusion Criteria: * Body weight between 50 and 85 kg, and Body Mass Index (BMI) between 17.6 and 26.4 kg/m2 inclusive Exclusion Criteria: * Medical history of metabolic disease, hepatic disease, heart disorder, respiratory disease, gastrointestinal disease, renal disease, cerebrovascular disorder, malignant tumor, drug allergy and drug/alcohol dependence * Blood pressure, pulse rate, body temperature and 12-lead ECG are outside of the preset normal range * Labo test results deviate from preset normal range * Receiving treatment, including medication, within 14 days before the study * Receiving medication in another clinical study or a post-marketing clinical trial within 3 months before the study * Donates 500mL of whole blood within 3 months or 250mL within 2 months or blood components within 14 days before the study * Drinking more than 45g of alcohol, or smoking more than 20 cigarettes per day * Employed by the sponsor, delegated CRO or the study site * Fasting plasma glucose level of \< 70 mg/dL or ≥110 mg/dL or with an HbA1c ≥5.8% * Subjects with positive serology test for Hepatitis B antigen, Hepatitis A virus IgM, anti-Hepatitis C virus or anti-Human Immunodeficiency virus-1 or -2